roche

Roche haemophilia therapy cuts bleed rate by 87%

pharmafile | June 26, 2017 | News story | Research and Development, Sales and Marketing Roche, haemophilia 

Roche has revealed new data on its investigational haemophilia therapy ACE910 (emicizumab) which shows an 87% reduction in bleed rate among patients who had become resistant to conventional treatment.

Resistance to treatment can disrupt attempts to control bleeding as a result of haemophilia, a disorder which prevents the blood for clotting as it should. The results of Roche’s late-stage trial showed that no treated bleeds were experienced by 62.9% of those using the drug, compared to 5.6% in patients treated with bypassing agents.

With this data, the company is hoping the treatment can fight off Novo Nordisk and Shire for a share of the haemophilia market – a space worth $11 billion per year. Analysts are valuing Roche’s new drug at $5 billion on the back of the new data.

Advertisement

However, the results also showed that repeated high doses of bypassing agents as a treatment for breakthrough bleeds led to adverse events including microangiopathy – the trial was even marked by the death of one patient – Roche said this was due to the participant refusing a blood transfusion on religious grounds.

Despite this, Roche plans to file for US regulatory approval later this year.

Matt Fellows

Related Content

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

blood_test

Roche candidate shows early promise for treating haemophilia A

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment …

The Gateway to Local Adoption Series

Latest content